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Using epidermal cells from psoriatic plaques as the 
immunogen, an lgG, murine monoclonal antibody, VM-
1, has been produced which stains basal keratinocytes 
on frozen sections of skin obtained from normal individ-
uals and from psoriatic plaques. In some areas of both 
normal and psoriatic epidermis, the cell layer immedi-
ately above the basal cells is also stained. Cells in the 
external root sheath of the hair follicles also bind VM-
1. The antibody binding site is trypsin-resistant, and is 
not blocked by bullous pemphigoid serum. 
If dispersed epidermal cells are preincubated with 
VM-1 for 1 h or more before plating, the majority of the 
cells do not attach and spread out on a collagen-coated 
Petri dish surface or on a fibroblast feeder layer. When 
added to attached, preconfluent cultures of keratino-
cytes, VM-1 inhibits growth and alters cell morphology. 
The growth inhibition is specific for keratinocytes, and 
viability studies show that it is not due to an immediate 
toxic effect of the antibody. The VM-1-induced inhibi-
tion of keratinocyte growth is not reversed by soy bean 
or lima bean trypsin inhibitors added at the time of cell 
plating or at the time of addition of antibody. 
The epidermis is a multicompartment system consisting of a 
proliferative pool containing stem cells located in the basal and 
suprabasallayers [1,2], and a differentiative compartment con-
taining cells of varying degrees of maturity within the spinous, 
granular, and horny layers. The signals and proximal stimuli 
that regulate stem cell proliferation are poorly understood, but 
are crucial to elucidating the role of these cells in normal 
epidermal growth, in hyperproliferative disease states such as 
psoriasis [3], and in carcinogenesis. 
In this communication we report the production of a unique 
murine monoclonal antibody, VM-1, which binds specifically 
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to the human keratinocytes within the basal and suprabasal 
proliferating pool, and which inhibits the attachment and 
growth of these keratinocytes in vitro. 
MATERIALS AND METHODS 
Using standard hybridoma techniques [4], SP 2/08A2 myeloma cells 
(a generous gift of Dr. Edgar Engleman) were fused with spleen and 
axillary lymph node cells obtained from a BALB/c mouse which had 
been immunized with trypsin-dispersed keratinocytes from psoriatic 
plaques from 2 unrelated donors. The hybridoma clones were screened 
on frozen sections prepared from both normal skin and from psoriatic 
plaques using the immunofluorescence technique described below. 
Isolation and Culture of Human Epidermal Cells 
Single cell suspension of skin cells were prepared from 0.4-mm split-
thickness skin from psoriatic plaques removed with a keratotome 
(Davol), or from normal full-thickness skin obtained at surgery. The 
skin was trimmed, cut into 1 X 5 em strips and split-cut with a 
Castroviejo keratotome (Storz Instrument Co., St. Louis, Missouri) set 
at 0.1 mm [5] . Strips of split-thickness skin were treated for 25 min at 
37' C with 0.3% trypsin (M. A. Bioproducts, Walkersville, Maryland) 
in 0.8% NaCl, 0.04% KCl, 0.1 % glucose, 0.084% NaHC03 , plus 0.1 % 
EDTA (pH 7.3). The skin slices were washed, transferred to Dulbecco's 
modified Eagle's medium (Gibco, Grand Island, New York), plus 10% 
heat-inactivated fetal calf serum (FCS), 50 l'g/ml gentamicin, 2 mm L-
glutamine, 50 units/ ml penicillin, and 50 l'g/ ml streptomycin (complete 
growth medium, CGM), and the basal and malpighian ce lls were 
released into the medium by gentle agitation. The cells of the stratum 
corneum remained as a cohesive monolayer and were left behind. For 
culture of epidermal cells, 2 X 106 viable, round, refractile cells obtained 
from normal skin were plated on a collagen thin gel-coated 3.5-cm Lux 
Petri dish (Flow Labs, Inglewood, California) or coseeded with irradi -
ated fibroblasts (see below) and incubated in 5% C0 2:95% air at 37'C. 
Viability before culture was generally over 80-90%. 
Attachment Assay 
Keratinocytes were preincubated at room temperature with VM-1 
(1:10 dilution of culture supernatant) or with conditioned myeloma 
medium (diluted 1:10) for 1 h and were then seeded, still in VM -1 or 
myeloma medium at 8 x 106 viable cells per 6-cm collagen-coated plate 
and incubated at 37' C. At 4 and 17 h, triplicate plates were carefully 
washed twice to remove nonattached cells, and then incubated with 3 
ml of 0.3% trypsin plus 1% EDTA and 0.3 % collagenase for 60 min at 
37' C to remove the attached cells. They were resuspended in complete 
medium and counted with a hemocytometer using trypan blue. 
Staining for Viability and the Presence of VM-1 on Culture Plates 
To determine viability of cultures, 0.1 ml of 0.01 % fluorescein 
diacetate (FDA) in phosphate-buffered saline (PBS)/acetone was added 
to each culture plate containing 1 ml of growth medium [6]. The plates 
were incubated in the dark for 5 min and rinsed 4 times with PBS; 0.5 
ml growth medium plus 50 Ill of0.04 % ethidium bromide (EB) in PBS 
were added to each plate, and the number of viable and dead cells was 
determined immediately using a fluorescence microscope. To detect 
binding of VM-1 , 0.5 ml of the antibody was added to the culture plate, 
which was incubated for 15-45 min at room temperature, washed twice 
with PBS, labeled with 0.5 ml fluorescein isothiocyanate-conjugated 
rabbit antimouse IgG (R/M-FITC) for 30 min at room temperature, 
washed twice with PBS, moistened with 0.2 ml 5% FCS/ PBS, and 
examined by fluorescence microsco):>y. 
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Immunofluorescence (!F) Staining of Frozen Sections of Shin or 
Dispersed Cells, FACS Analysis, and Panning 
The bindin g of ant ibodies to epidermal ce lls in situ was determined 
by lF using R/M-FITC (Miles Laboratories, E lkhart, Indiana) which 
had been preabsorbed on dispersed human skin cells. Frozen sections 
of skin were incubated with monoclonal antibody in humidified glass 
Petr i dishes for 20 min at room temperature, washed with PBS, labeled 
with R/M-FITC for 15 min and washed with PBS [7]. Sections were 
covered with fluorescent ant ibody mounting fluid (DIFCO, Detroit, 
Michigan) and exam ined wi th a Zeiss flu orescence microscope. Tryp-
sinized cell suspensions were labe led in a similar manner, and a liquots 
were resuspended in 5% FCS/PBS, placed on a slide, cove red with a 
glass coverslip, and exam ined. 
Staining for FACS analys is was as previously described [8], using 
VM -1 and a second-stage goat antimouse lgG (Tago Inc, Burlingame, 
Cali fornia). T he stained cells were analyzed on a FACS III (Becton 
Dickinson, Sunnyvale, California) that was coupled to a PDP-11 com-
puter. Controls included unstained cells and samples incubated with 
the second stage only. 
The panning procedure was similar to that used by Wysocki and 
Sato [9] and Morhenn et al [10] . In brief, the epidermal cells were 
stained with bullous pemph igoid serum obtained from a volunteer and 
incubated on Petri dishes coated with affin ity-purified goat-antihuman 
lg (Tago) for 45- 60 min at 4"C. Adherent cells were removed with 
vigorous pipetting or with a rubber policeman. 
Immunoperoxidose (IP) Labeling of Frozen Shin Sections 
Frozen sections of human skin were labeled using an immunoperox-
idase staining technique [11]. Briefly, the tissue was fixed with acetone, 
incubated with VM-1 for 20 min, washed with PBS, incubated with 
biotin-conjugated goat-antimouse lgG (G/M-IgG) (Tago, Inc.) , washed 
with PBS, labeled with avidin-conjugated horseradish peroxidase (Vec-
tor Labs, Burlingame, Cal ifornia) for 15 min, washed with PBS and 
H20 , incubated with fresh diaminobenzidine solution for 5 min, and 
rinsed with PBS and H20. The sections were processed in 0.5% CuSO, 
solution, counterstained with Giemsa, cleared, and mounted. 
Isolation and Culture of Fibroblasts, Peripheral Blood Mononuclear 
Cells, and T -Cell Lines 
Human fibroblasts were derived from a piece of normal fores kin 
using an explant method [1 2]. 3T 3-J2 cells (a kind gift from Dr. Howard 
Green) were subdivided twice a week. For feeder layers 2 x 106 3T 3 
ce lls/m l were exposed to 8000 rads in a cesium irradiator and coseeded 
with the keratinocytes. Mononuclear cells were isolated from defibri -
nated peripheral blood by centrifugation on a Ficoll -Hypaque gradient 
[13]. The HUT-78 human T-lymphoma cell line was a gift of Dr. J. 
Minna, and the MOLT-4 and HPB-ALL cell lines a gift of Dr. R. Levy. 
Determination of Thymidine and Leucine Incorporation and DNA 
Content 
Epidermal cell cultures were incubated with [3H]thymidine ([3H] 
dThd) (3 fLCi / ml) (New England Nuclear , Boston, Massachusetts) for 
1 h or with [3H]leucine ([ 3H]Leu) (2 fLCi/ml) (New England Nuclear) 
for 2 h. The plates were washed with PBS, and 2 ml 5% trichloroacetic 
ac id (TCA) was added. The precipitate was scraped into a test tube, 
homogenized and centrifuged, the pellet washed wi t h 5% TCA, collected 
by cent rifugation, and dissolved in 0.5 N NaOH. An aliquot was taken 
for DNA determination using the ethidium bromide technique [14]. 
RESULTS 
Production of VM-1 
The fusion produced 20 stable hybridomas. All were screened 
on frozen sections of normal and psoriatic human skin, and 
one, VM-1 (previously called W-13), showed basal cell layer 
binding and was chosen for further study [15]. It was subcloned 
3 t imes by limit ing dilution and found to be an lgG 1 by Ouch-
terlony immunodiffusion aga inst antigammah and anti-7s an-
tibodies. 
Specificity of VM-1 
VM-1 binds strongly to the basal keratinocyte layer and, in 
focal areas, to cells immediately above this layer in normal 
human epidermis (Fig 1) [15]. Skin taken from psoriatic plaques 
bas similar basal laye r staining. Particularly in the rete ridge 
of the psoriatic epidermis, the juxtabasalar cell layer also binds 
t he antibody (data not shown). VM-1 also labels t he epithelial 
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FIG 1. Frozen section of normal human skin stained with VM-1 and 
R/M-FITC. Only the basal cell , and, in some areas, the suprabasal cell 
layers are stained. d = Dermis. X 100. 
FIG 2. Frozen section of normal skin stained with VM -1 plus IP. 
The cells of the external root sheath (arrow) of the hair follicle are 
stained. D = dermis. X 250. 
cells of t he outer root sheath of the hair follicle in normal skin 
(Fig 2). This can best be judged using the IP technique, since 
the cells of the hair follicle exhibit marked autofluorescence, 
making the IF determination of specific stain ing difficult. No 
other cells in the dermis or epidermis are stained. 
Staining of Various Cell Suspensions with VM-1 
To determine whether trypsinized epidermal cells retain the 
capacity to bind the antibody, dispersed normal epidermal cells 
were stained with VM-1 and R/M FITC and the number of 
labeled cells determined by fluorescence microscopy (Fig 3). 
The separation procedure yielded cells mainly from the basal 
and spinous layers (V. Morhenn, unpublished data). In 2 ex-
periments, 37% and 56% of the dispersed cell population 
stained specifically with VM-1 (Table I); the fluorescence 
brightness depended on the antibody concentration (not 
shown). In contrast, dispersed fibroblasts from human foreskin , 
peripheral blood mononuclear cells, and 3 human T -lymphoma/ 
leukemia cell lines had no staining. VM -1 thus differs from 
4F2, an antibody which binds to both lymphoid and basal cells 
[16,17] . 
Dispersed keratinocytes stained with VM-1 and R/M-FITC 
were also analyzed by flow cytometry. Forty-s ix percent of the 
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FIG 3. Dispersed normal human kerat.inocytes were stained wit h 
VM-1, a nd R/M-FITC and examined by fluorescence microscopy. Cell 
su rface fl uorescence is seen on some of t he cells. Cells stained with R/ 
M-FITC alone demonstrated no fluorescence. X 750. 
TABLE I. Binding of VM- I to cells in suspension 
Dispersed ce ll type 
Epidermal ce lls 
F ibroblasts 
H UT (- 78) 
MOLT-4 
H P B-ALL 
Peripheral blood 
mononuclear 
leukocytes 
Number of cells labeled with VM-1 
{% cont rol) 
Experiment 1 a Experiment 2a Experiment 3b 
56% 
0 
0 
0 
0 
0 
37% 
0 
0 
0 
0 
0 
46% 
ND' 
ND 
ND 
ND 
0 
" Imm unofl uorescence microscopy. 
h FA CS analys is. 
' ND = not done. 
cells stained above background (T able I) . T he VM- 1 +cells gave 
a s ingle low-angle light scatte ring peak. The median light 
scatte r was smaller t han t hat of t he VM -1- cells, as is consistent 
with t heir microscopic appearance (data not shown ). 
T o determine whet her the epidermal separation technique 
caused addi t ional cells to bind VM-1, dispersed keratinocytes 
were stained with bullous pemphigoid serum (BPS) and panned 
on goat-ant ihuman l gG -coated plates. Adherent and non-
adherent cell s were t hen stai ned with VM-1 and G/M FITC 
and t he pe rcent of VM-1+ cell s determined by fluorescence 
microscopy. Ninety-two percent of t he adherent (BPS+) cells 
also stained with VM-1, while 11% of t he non-adherent cells 
were VM-1 +.Thus, VM-1 binds to cells t hat carry t he pemphi-
goid ant igen. The BPS nonadherent, VM -1 + cells may corre-
spond to t he juxtabasalar sta ining seen in t issue sections. 
Effect of VM-1 on Keratinocyte Attachment 
Epidermal ce lls incubated wi th VM-1 (1:10 dilution of culture 
supernatant) for 1 h at 4 ·c or at room temperature have no 
change in viabili ty by FDA/EB staining or t rypan blue exclu-
sion. However, when the antibody-coated ce lls are seeded onto 
a collagen-coated dish, markedly fewer cells attach to the 
surface compared to cont rol cul tures. The majority remain as 
round, refractil e, nonadherent cells. T he attachment of kerat-
inocytes to a collagen-coated plastic surface was quant itated at 
2 t ime poin ts. Compared to control cul tures only 37% of ~he 
VM-1 pretreated keratinocytes attached by 4 h after seedmg 
(Table II ). After 24 h, t he number of attached cells in t he VM-
1 pretreated cul tures was only about 60% of control. Thus, 
VM-1 binding to keratinocytes prevents in vit ro attachment 
and/or spreading out on collagen gel. In a similar series of 
experiments, keratinocytes were seeded wit h irradiated (8000 
rads) 3T3 fibroblasts as feeder layers with or without VM -1. 
Afte r 10 days of cul ture, t he cont rols showed many large islands 
of keratinocytes whereas t he VM-1 treated cult ures showed 
only a rare small group of keratinocytes. T hus, VM-1 also 
inhibits keratinocyte attachment or growth on fibroblast-con -
di t ioned substrates. 
If cells are seeded on collagen-coated dishes and VM -1 (1:10 
dilut ion) is added 24 or 48 h after seeding before t he cultures 
have become confluent, many of the cells t hat have already 
attached round up. This process occurs within 4 h in noncon-
fluent areas of t he dish and does not reverse over extended 
periods in culture (Fig 4) . In lqcal regions where the cells a re 
confluent or in cultures that have been allowed to grow to 
T ABLE II. Inhibition of the attachment of keratinocytes preincubated 
with VM- 1 
T ime of assay" 
4 h 
24 h 
Percent of viable, 
adherent cells/ plate 
{% cont rol)' 
37 ± 2.6' 
60.5 ± 9.2 
o Cells were incubated with VM-1 before seeding. Attachment was 
quant itated afte r 4 and 24 h. 
h (Number of attached cells pretreated with VM-1)/ (Number of 
attached cells pretreated with cont rol ant ibody) X 100. 
' Mean ± SD (4 experiments) . 
FIG 4. a, Normal human keratinocytes were seeded onto collagen 
plates and at 24 h VM-1 (diluted 1:10) was added. On day 6, cultu res 
were fi xed, stained, and photographed with an inverted t issue culture 
microscope (X 25). b, Control cultures ha rvested on the same day ( X 
25). 
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uniform confluence before VM-1 is added, little or no visible 
effect of VM -1 is seen. 
A consistent finding in preconfluent cultures incubated with 
VM-1 is the persistence of small numbers of strongly adherent 
cells that develop dendritic processes. As shown in Fig 4, the 
rounded cells tend to remain attached to these adherent cells 
during culture. The adherent cells are relatively resistant to 
trypsinization (0.3 trypsin/1% EDTA) and have to be removed 
from t he culture surface with a rubber policeman. 
Effect of VM-1 on the Viability of Cultured Keratinocytes 
To determine whether the morphologic alterations induced 
by VM-1 were due to direct toxicity of the antibody, 24 h after 
seeding replicate plates of ep idermal cell s were treated with 
either VM-1 or a control IgG1 murine monoclonal antibody 
that does not bind to human keratinocytes. Petri dishes were 
harvested 6 and 24 h after addition of antibody. The adherent 
and nonadherent cells were stained for viabili ty, and in separate 
plates the cellular binding of VM-1 was determined. Six hours 
after add ition of the antibody when the morphologic effect of 
VM-1 was already apparent, no significant difference between 
the viability of attached cells in VM-1-treated dishes and 
controls was found; each set of dishes contained over 90% 
viable, attached cells. The detached cells pelleted from the 
supernatant medium showed a viabil ity of 40 ± 2% in t he VM-
1-treated plates and 34 ± 3% in the control plates. Most of the 
VM-1-treated cells on the Petri dish surface demonstrated 
specific fluorescence with R/M-FITC. Thus, VM-1 binds to 
attached cells and alters morphology without immediately caus-
ing cell death. No significant difference was seen in the R/M-
FITC staining of supernatant cells removed from VM-1-treated 
or from control cultures. 
Twenty-four hours after addition of the antibody, most of 
the attached cells bound VM -1 whereas no specific stain ing 
was seen in the controls treated with nonspecific IgG 1 • Again, 
almost all of the attached cells were viable in both VM-1 - and 
nonspecific lgG1 -treated plates. Supernatant cells in both series 
were over 95% dead, and no specific binding of VM-1 to these 
cells was seen. Thus, VM-1 can alter keratinocyte adherence 
in the absence of immediate toxicity. 
Effect of VM-1 on Keratinocyte Growth and on DNA and 
Protein Synthesis 
In keratinocyte cultures treated with a 1:10 dilution of VM-
1, t he total DNA content per plate decreases during 13 days in 
culture (Fig 5) . By contrast, control cultures (untreated or 
treated with a nonspecific monoclonal IgGd show about a 4-
fold increase in DNA content during this t ime (Fig 5). DNA 
synthesis in the VM-1-treated attached cell s also is signifi-
cantly inhibited, especially on day 6 when synthesis in the 
., 3 
0 
Ci. 
' <l 2 
z 
0 
~I 
/:~ 
:~:~----·-·- ----·":_· '" ·~: . . . -·· .. . . 
2 • 6 8 10 12 .. · · ·········· · .~
-~·-r· .. olt•r .. ~.b - oddltl:n~
:~· 
. ---- -- ------·-----------------·- ------------· 
4 !5 6 8 9 10 II 12 13 
day s after Ab addition 
F tG 5. Keratinocytes were seeded, and at 24 h CGM control or a 
dilution of VM-1 or of a nonspecific gamma, monoclonal (MOPC-21) 
was added. Total DNA content per plate and synthesis of DNA 
(inset) were assayed on days 2, 6, 10, and 13. (e e) controls; 
(X---X) VM-1; (* ••• *) MOPC-21. SEM < 18%. 
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TABLE IlL Inhibition of keratinocyte ["H) leucine incorporation by 
VM-1 
Days after [' H]leucine incorporation• 
seeding" Control cultures VM-1 treated" 
4 3422 ± 257 1060 ± 124 
8 2110 ± 266 921 ± 62 
11 1560 ± 94 734 ± 30 
• Time after seeding of cultures (see text). 
b Mean cpm/ ~'g DNA ± SD. 
Percent 
inhibi-
tiond 
75 
63 
49 
< VM-1 culture supernatant (1:10) added 24 h after seeding. 
d Percent inhibition= [1 -(cpm/i.<g DNA with VM-1)/(cpm/!Lg DNA 
with control)] X 100. 
control cultures is maximaL To control for varying numbers of 
attached cells in the VM-1-treated plates and for the prolifer-
ation of the control cultures, the [3H]dThd incorporation data 
have been normalized to the total DNA on each plate. 
Because inhibition of the rate of incorporation of [3H)dThd 
into acid-insoluble material may not accurately reflect the rate 
of cellular DNA synthesis in keratinocytes [18], we used [3H] 
Leu incorporation into protein as another marker for measuring 
cellular growth. Keratinocyte cultures were seeded and 24 h 
later VM-1 (diluted 1:10) was added to replicate culture dishes. 
[3H]Leu incorporation was assayed on days 4, 8, and 11 after 
seeding and normalized to the total DNA. As shown in Table 
III protein synthesis was inhibited significant ly by VM-1. On 
days 4, 8, and 11, VM-1-treated cultures were inhibited by 75, 
63 and 49%, respectively. Thus, VM-1 binding inhibits both 
DNA and protein synthesis. 
As a control for a nonspecific effect of VM-1, 2 other murine 
monoclonal antibodies which bind to epidermal cells were 
tested on cultured keratinocytes. One of these antibodies (VM-
2) also labels basal cells, the other labels the majority of the 
cells of the epidermis. Neither antibody affected the growth of 
the keratinocytes over a 6-day period. As further controls, 
supernatant media from the parent myeloma cells and an IgG1 
monoclonal antibody which does not stain human skin (MOPC-
21) cells were added to the cultures at a 1:10 dilution. Again, 
there was no effect on keratinocyte growth. 
VM-1 (diluted 1:10) was also added to human foreskin fibro-
blasts either at the time of seeding the cells or at 24 h later. In 
neither of these cultures did the antibody VM-1 inhibit attach-
ment or growth of the fibroblasts over a 5-day period, at which 
time the cells were confluent. 
The Effect of Proteinase Inhibitors on VM-1-lnduced Changes 
in Morphology and Growth 
Recent studies have shown that keratinocyte-binding anti-
bodies from patients with pemphigus vulgaris can cause de-
tachment of cultured keratinocytes, and that this effect can be 
blocked by soybean trypsin and lima bean trypsin inhibitors 
[19). Similar results have also been reported for cultured mel-
anoma cells (20] . We therefore investigated the possibility that 
VM-1 binding released or activated comparable proteolytic 
enzymes. 
Soybean trypsin inhibitor (SBTI) (100 J.tg/ml and 400 J.tg/ 
ml) was added to keratinocytes at the time of seeding in the 
presence or absence of VM-1. Other replicate cultures received 
SBTI (500 J.tg/ml and 1 mg/ml) plus VM-1 (diluted 1:10) at 24 
h after cell seeding. Lima bean trypsin inhibitor (LBTI) (400 
J.tg/ml) was added 2 h after seeding epidermal cells and VM-1 
was added 22 h later. SBTI and LBTI under these conditions 
did not prevent the antibody-induced inhibition of attachment 
to the culture surface. The cultures receiving either of the 
inhibitors plus VM-1 exhibited the same cell detachment and 
inhibition of growth as did cultures treated with VM-1 alone 
(not shown). SBTI or LBTI added to cultures without VM-1 
did not alter keratinocyte growth. In a separate experiment, 
LBTI (400 J.tg/ml) was added to keratinocyte cultures after 
seeding, and again after 24 h together with VM-1 or control 
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medium. [3H]Leu incorporation/i<g DNA was assayed after an 
additional 3, 7, and 10 days. In t he presence of LBTI, VM-1 
inhibited protein synthesis by 70, 50, and 45% at t he 3 t ime 
points, respectively, s imilar to the experiments summarized on 
Table III . LBTI alone did not block protein synthesis. Thus, 
t he effect of VM-1 on keratinocytes was not reversed by pro-
teinase inhibitors. 
DISCUSSION 
We have produced a murine monoclonal IgGI antibody, VM-
1, which binds specifica lly to cells within the proliferating 
compartment of hu man epidermis. In normal skin , it stains the 
basal cell layer and in focal areas the juxtabasal cells. In skin 
obtained from psoriatic plaques, the suprabasal staining is more 
pronounced, in agreement with previous studies using [JH] 
dThd [21-23). As expected, VM-1 also binds to the external 
root sheath of hair follicles. The fraction of VM-1+ cells in -
cludes t he populat ion of cells carrying the bullous pemphigoid 
antigen. It may be somewhat larger, because VM-1 also sta ins 
some juxtabasala r cells . The antibody does not stain t he dermis, 
but it does bind to infiltrating basa l cell carcinoma and to at 
least some squamous cell carcinomas [24 ). In contrast to 4F2 
which also stains basal kerat inocytes [16], VM-1 does not bind 
to peripheral blood mononuclea r cells or to 3 different T-cell 
lines. The VM-1 binding site is trypsin-resistant, and is not 
blocked by BPS. Forty to fifty percent of dispersed epidermal 
ce lls iso lated from normal skin stain wit h the antibody. This 
relatively high percentage suggests t hat our separat ion proce-
dure enriches for basal cells, perhaps because the upper layers 
of the epidermis are not disaggregated. 
VM -1 binding may be a useful assay for proliferative capacity. 
P reliminary experiments with cult ured keratinocytes show t hat 
VM-1 staining progressively decreases with each passage (V. 
Morhenn, unpublished data). This may imply that passaged 
keratinocytes undergo terminal different iation in culture and 
is consistent with the fact t hat cells derived from adult skin 
cannot be subcul tured more t han 2 or 3 times under t hese 
condit ions of cu lture [5]. 
Incubation of dispersed ep idermal cells with VM-1 prevents 
attachment of 30- 60% of t he cells to a co llagen-coated dish. 
This value for t he inhibition of attachment is consistent with 
t he interpretation that t he subpopulation of epidermal cells 
which binds VM-1 can no longer attach and spread out on 
cu lture substrate. If the ant ibody is added to preconfluent 
cultures, most of the cells rapidly change t heir morphology and 
round up on t he di sh. As shown in Fig 4, at least some cell -to-
cell contacts appear to be maintained. However, some of the 
cells that remain attached to t he dish after incubation with 
VM-1 also bind t he antibody. It is not clear whether these cells 
consti tute distinct subpopulations or whether t he continued 
attachment refl ects, for example, differences in t he number of 
VM-1 binding sites available on t he cell surface. 
Although VM-1 is not directly tox ic to keratinocytes, it 
inhibits proliferation of primary cultures as assayed by [3H ] 
dThd and eHJLeu incorporation . Recent experiments in which 
human skin was gra fted onto nude mice and VM-1 administe red 
systemically suggest t hat it also inhibits keratinocyte prolifer-
ation in this in vivo model [25). 
The mechanism(s) producing morphologic changes and 
growth inhibi t ion do not appea r to be related to t he activi ty of 
proteinases that have been described in other systems 
[18,19,25]. It is possible that VM-1 binds to a cell surface 
structure which is necessary for attachment to the substrate, 
or t he antibody might induce changes in the cytoskeleton of 
the cell. In eit her case, inhibi t ion of growth might be related to 
inadequate attachment to t he cul ture dish [27,28]. Alterna-
tively, VM-1 may block a cell surface receptor necessary for 
growth (e.g. , epidermal growth factor) [29]. 
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